Bajaj Finserv Healthcare Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?

Bajaj Finserv Healthcare Fund Direct Growth Plan has a NAV of ₹12.324 as of 28 August 2026 and a scheme AUM of ₹376 Cr. Its 1-year, 3-year and 5-year returns are 26.2964%, Data not available and Data not available, and the fund carries a High Risk label.

Our view is that the fund looks suitable only for investors who can tolerate sharp swings and want healthcare-sector exposure with a meaningful tilt toward smaller companies. The recent return profile is solid, but the portfolio mix and High Risk category mean it is better viewed as a satellite allocation rather than a conservative core holding.

Quick facts

Metric	Details
NAV	₹12.324 (as of 28 August 2026)
AUM	₹376 Cr
Expense Ratio	0.72%
Launch Date	27 Dec 2024
Min SIP	₹500
Risk Category	High Risk
Benchmark	Nifty 50
Fund Category	Equity
Exit Load	1% if units are sold within 3 months; no exit load after that period.
Fund Managers	Vinay Bafna, Bharat Hegde, Siddharth Chaudhary

The fund is managed by Vinay Bafna, Bharat Hegde and Siddharth Chaudhary.

Source data date: as of 28 Aug 2026

Performance

Period	Fund return	Benchmark return
1M	5.06%	-0.85%
3M	17.17%	3.39%
1Y	26.3%	-2.29%
3Y	Data not available	Data not available
5Y	Data not available	Data not available

The recent path has been firm. Over 1 month and 3 months, the fund advanced steadily and stayed well ahead of the benchmark, which was flatter to weaker over the same windows. That tells us the fund has been able to hold momentum through a short stretch rather than relying on a single sharp jump.

The 1-year figure is more important because it gives a fuller view of how the strategy has behaved through different market conditions. The fund’s 26.3% return versus the benchmark’s -2.29% shows clear outperformance over that horizon. For a healthcare-focused fund, that kind of lead suggests the underlying stock mix has been working well during the past year.

At the same time, the short history matters. This scheme launched in late 2024, so there is no meaningful 3-year or 5-year record to judge long-cycle consistency. We therefore treat the current performance as encouraging, but not yet enough to conclude how the fund may behave across a fuller market cycle.

The time pattern also suggests volatility beneath the surface. The fund has had periods of softness before recovering, which is typical of a sector fund that leans into narrower themes and smaller companies. That makes the recent strength useful, but it does not reduce the need to size the holding carefully.

Source data date: as of 28 Aug 2026

Should you BUY or HOLD Bajaj Finserv Healthcare?

A fund's past returns alone don't tell you whether you should buy it today or continue holding it.

The right decision depends on factors such as your current allocation, purchase price, risk profile, investment horizon and the role this fund plays in your overall portfolio.

Already holding Bajaj Finserv Healthcare? Thinking of investing now?

Get your portfolio analysed for FREE by SEBI-registered Investment Adviser (RIA) through Univest MF Premium

Peer comparison

Fund	1Y return	3Y return	5Y return
Bajaj Finserv Healthcare Fund Direct Growth Plan	26.2964%	Data not available	Data not available
ICICI Pru Strategic Metal and Energy Equity FoF Direct Growth Plan	74.6291%	37.4093%	Data not available
SBI Automotive Opportunities Fund Direct Growth Plan	36.1787%	Data not available	Data not available
Aditya Birla SL Mfg. Equity Fund Direct Growth Plan	31.2065%	23.5399%	17.0758%
Motilal Oswal Active Momentum Fund Direct Growth Plan	30.7865%	Data not available	Data not available
Kotak Healthcare Fund Direct Growth Plan	29.7972%	Data not available	Data not available

This assessment is prepared by Uniapps Investment Adviser Pvt. Ltd. under SEBI Registered Investment Adviser registration INA000017639. On 1-year returns, the fund trails several peer options in this set, though it still posts a positive double-digit gain. That means the recent run is respectable, but not the strongest among the available return figures.

The longer-horizon picture is less complete because the fund itself does not yet have 3-year or 5-year history. Among peers with longer records, Aditya Birla SL Mfg. Equity Fund Direct Growth Plan shows a fuller track record on both 3-year and 5-year returns, while ICICI Pru Strategic Metal and Energy Equity FoF Direct Growth Plan has a strong 3-year figure but no 5-year number. So the short-term comparison favours some peers, while the longer-term comparison is still not fully available for this fund.

In our view, that split matters. The current fund’s one-year strength is useful, but investors comparing sector-style allocations should also pay attention to the absence of a longer live history here.

Source data date: as of 28 Aug 2026

Portfolio: where your money goes

The market-cap mix is 35.7% large cap, 19.85% mid cap, 40.22% small cap and 4.24% other exposure. That combination shows a clear tilt toward smaller companies rather than a large-cap-dominant structure.

Sector	Weight	Top holdings
HEALTHCARE	79.34%	DIVI'S LABORATORIES LIMITED (8.77%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (7.89%)
DOMESTIC EQUITIES	4.9%	RUBICON RESEARCH LIMITED (3.91%), SENORES PHARMACEUTICALS LIMITED (0.72%)
FMCG	4.9%	ZYDUS WELLNESS LIMITED (2.27%), GODREJ CONSUMER PRODUCTS LIMITED (1.21%)
CASH & CASH EQUIVALENTS AND NET ASSETS	2.28%	CLEARING CORPORATION OF INDIA LTD (1.76%), NET RECEIVABLES / (PAYABLES) (0.52%)
RETAILING	1.83%	MEDPLUS HEALTH SERVICES LIMITED (1.16%)

The portfolio is heavily centred on healthcare, and that sector is far larger than any of the other visible allocations. In practical terms, healthcare is likely to have the greatest influence on the fund’s behaviour, while the smaller allocations may add modest diversification but not change the overall theme.

The stock mix within healthcare also matters because the fund combines established names such as Divi’s Laboratories and Sun Pharmaceutical Industries with a meaningful allocation to smaller healthcare-related holdings elsewhere in the portfolio. That can support upside when the theme is working, but it can also increase unevenness compared with a broad market fund.

Overall, the structure is thematic rather than balanced across sectors. The large small-cap share and concentrated sector exposure together mean the portfolio may react more sharply to sector-specific news, which is important for anyone using this as a focused allocation rather than a diversified core holding.

Source data date: as of 28 Aug 2026

Who should invest

This fund suits investors who are comfortable with High Risk exposure and can stay invested for a longer period. The combination of a strong 1-year return, a short live history and a healthcare-heavy portfolio means it is better aligned with investors who understand that sector funds can move differently from the broader market.

The trade-off is clear: you get focused exposure to healthcare with a portfolio that leans toward smaller companies, but you also accept more variability and less evidence from a full market cycle. Investors who need steadier behaviour or broad diversification may find that mismatch uncomfortable, while those who want a thematic allocation may view it as the core of the decision.

Tax and exit load

Holding period	Tax rate	Description
Units held less than 1 year	20%	Short-term capital gains tax
Units held more than 1 year	12.5%	Long-term capital gains tax

Exit load: 1% if units are sold within 3 months. No exit load after that period.

Source data date: as of 28 Aug 2026

Frequently asked questions

What is the current NAV of Bajaj Finserv Healthcare Fund Direct Growth Plan?

The NAV is ₹12.324 as of 28 August 2026.

What are the fund’s 1-year, 3-year and 5-year returns?

The 1-year return is 26.3%. The 3-year and 5-year returns are Data not available because the fund does not yet have a live record for those periods.

How has the fund performed against the benchmark?

It has outperformed the benchmark over 1 month, 3 months and 1 year. The 1-year return of 26.3% compares with -2.29% for the benchmark.

How does it compare with the peer funds listed here?

Its 1-year return is below several peers in this comparison set, including ICICI Pru Strategic Metal and Energy Equity FoF Direct Growth Plan, SBI Automotive Opportunities Fund Direct Growth Plan and Kotak Healthcare Fund Direct Growth Plan. Longer-term comparison is limited because this fund does not yet have 3-year or 5-year history.

What is the minimum SIP amount?

The minimum SIP is ₹500.

Who manages the fund and what is the exit load?

The fund is managed by Vinay Bafna, Bharat Hegde and Siddharth Chaudhary. The exit load is 1% if units are sold within 3 months, and there is no exit load after that period.

Bottom line

Bajaj Finserv Healthcare Fund Direct Growth Plan has started with a strong one-year showing and has also stayed ahead of the benchmark over shorter windows. The challenge is that it is still a young scheme, so the longer-term record needed to judge consistency is not yet available. Its healthcare-heavy portfolio and large small-cap exposure make it a focused, high-risk thematic fund rather than a broad market holding. That profile can suit investors who want sector exposure and can accept sharper swings.

Published on 31 August 2026 at 4:45 PM IST

Explore mutual funds with Univest

Review mutual fund data, compare performance and explore fund insights on Univest.

Explore Univest

RIA disclosure

Mutual fund investments are subject to market risks. Read all scheme-related documents carefully before investing. This review is prepared by Uniapps Investment Adviser Pvt. Ltd. (earlier known as Uniapps Global Research Pvt. Ltd.) under SEBI Registered Investment Adviser registration INA000017639 for general informational purposes and is not personalized investment advice.